NCT05059743View on ClinicalTrials.gov

ADME Study of [14C]- Larotinib in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 20, 2021

Primary Completion Date

January 10, 2022

Study Completion Date

January 10, 2022

Conditions
Healthy Adult Male Volunteers
Interventions
DRUG

[14C]-Larotinib

Patients will receive single dose of orally \[14C\]-Larotinib on Day 1.

Trial Locations (1)

Unknown

Jiangsu Province Hospital, Nanjing

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT05059743 - ADME Study of [14C]- Larotinib in Healthy Male Subjects | Biotech Hunter | Biotech Hunter